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Abstract:  
Background & Aims: Biopsy-confirmed liver fibrosis is a prognostic factor for 
patients with non-alcoholic fatty liver disease (NAFLD). We performed a systematic 
review to quantify the prognostic value of fibrosis stage in patients with NAFLD and 
the subgroup of patients with non-alcoholic steatohepatitis (NASH) and to assess the 
evidence that change in fibrosis stage is a surrogate endpoint.  
Methods: We searched the MEDLINE, EMBASE, Cochrane Library, and trial 
registry databases through August 2018 for prospective or retrospective cohort 
studies of liver-related clinical events and outcomes in adults with NAFLD or NASH. 
We collected data on mortality (all-cause and liver-related) and morbidity (cirrhosis, 
liver cancer, and all liver-related events) by stage of fibrosis, determined by biopsy, 
for patients with NAFLD or NASH. Using fibrosis stage 0 as a reference population, 
we calculated fibrosis stage-specific relative risk (RR) and 95% CI values for 
mortality and morbidities. We performed fixed-effect and random-effect model meta-
analyses. Meta-regression was used to examine associations among study design 
(prospective vs retrospective cohort), overall risk of bias (medium or high), and mean 
duration of follow up (in years). 
Results: Our meta-analysis included 13 studies, comprising 4428 patients with 
NAFLD; 2875 of these were reported to have NASH. Compared to no fibrosis (stage 
0), unadjusted risk increased with increasing stage of fibrosis (stage 0 vs 4): all-
cause mortality RR, 3.42 (95% CI, 2.63–4.46); liver-related mortality RR, 11.13 (95% 
CI, 4.15–29.84); liver transplantation RR, 5.42 (95% CI, 1.05–27.89), and liver-
related events RR, 12.78 (95% CI, 6.85–23.85). The magnitude of RR did not differ 
significantly following adjustment for confounders including age or sex in the 
subgroup of NAFLD patients with NASH. Three studies examined the effects of 
increasing fibrosis on quality of life had inconsistent findings.  
Conclusions: In a systematic review and meta-analysis, we found biopsy-confirmed 
fibrosis to be associated with risk of mortality and liver-related morbidity in patients 
with NAFLD, with and without adjustment for confounding factors and in patients with 
reported NASH. Further studies are needed to assess the association between 
fibrosis stage and patient quality of life and establish that change in liver fibrosis 
stage is a valid endpoint for use in clinical trials. 
 
KEY WORDS: biomarker, disease progression, prognosis, liver disease  
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) has become a major health problem 
because of its potential to evolve into cirrhosis with consequential risks of death and 
morbidity, including hepatocellular carcinoma and liver transplantation.1 NAFLD is 
defined as fatty change (steatosis) affecting greater than 5% of hepatocytes, and has 
a spectrum of histological features ranging from steatosis without fibrosis to non-
alcoholic steatohepatitis (NASH) with varying stages of fibrosis.2 The Fatty Liver 
Inhibition of Progression Steatosis-Activity-Fibrosis (SAF) criteria and the NASH 
Clinical Research Network (CRN) NAFLD Activity Score are the most widely adopted 
semiquantitative scores used for assessing histological disease activity.3 To sustain 
a diagnosis of NASH, both require histological evidence of the presence of steatosis, 
hepatocyte ballooning and lobular inflammation. In patients with NAFLD, it is widely 
accepted that liver fibrosis develops as a result of liver injury secondary to 
steatohepatitis. Given that disease activity in NASH may fluctuate over time and liver 
biopsy may be subject to sampling variability, some patients with NASH may be 
miscategorised as not having NASH. Moreover, the fibrosis progression rate and the 
proportion of individuals with NAFLD having fibrosis progression was similar in a 
long-term study in with paired patient liver biopsies according to whether or not they 
had NASH at baseline.4  
Observational studies have shown biopsy-confirmed liver fibrosis to be a major 
prognostic predictor of liver-related and overall mortality in patients with NAFLD.5 
Thus, liver fibrosis is deemed a putative surrogate for disease outcome and so 
reduction in fibrosis is commonly used as a primary endpoint in clinical trials of 
treatments for NASH.6 Surrogate endpoints allow for the earlier assessment of the 
benefits of treatments without waiting for longer-term, final patient-relevant outcomes 
to accrue, such as hepatocellular cancer, cirrhosis, liver failure, liver transplant or 
death. However, regulators such as the US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) and payers typically only accept surrogate 
endpoints if their validity has been proven. In addition to evidence of their biological 
and pathophysiological plausibility, evidence of validation requires demonstration of 
the association between the treatment effect of the surrogate (e.g. a reduction in 
biopsy-confirmed fibrosis stage) and a relevant clinical outcome (e.g. reduced liver-
related mortality) in the setting of a single (or multiple) randomised controlled trial 
(RCT).6,7  
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A systematic review and meta-analysis including five observational cohort studies 
(1,495 NAFLD patients) assessed liver fibrosis as a prognostic marker of mortality.8 
The authors reported that patients with NAFLD and fibrosis were at increased risk of 
overall and liver-related mortality and that this risk was related to advancing fibrosis 
stage. However, this previous study was subject to a number of limitations: (1) a 
small number of studies and a sparse number of events (a total of 56 liver-related 
deaths) meant the meta-analysis results were potentially less precise and also 
subject to bias; 9,10 (2) only considered the outcome of mortality; (3) the comparison 
between fibrosis stage and death did not account for the potential confounding by 
factors such as age, gender, and statin usage; (4) did not include analyses of the 
impact of liver fibrosis in the subgroup of NAFLD patients with NASH; and (5) the 
study did not consider the question of change in liver fibrosis as a putative surrogate 
endpoint. Furthermore, we are aware of the publication of additional primary studies 
since the literature searches (up to November 2016) of this prior review.  
The overarching aim of this study was to undertake a systematic review and meta-
analysis to assess the evidence for stage of liver fibrosis as a predictor for mortality, 
liver-related morbidity and health-related quality of life (HRQoL) in patients with 
NAFLD and the subgroup with NASH. The specific research questions that we 
sought to address were: (1) What is the evidence for liver fibrosis as a prognostic 
marker of mortality, morbidity, and HRQoL in NAFLD and NASH? (2) What is the 
evidence for the change in liver fibrosis as a valid surrogate endpoint for mortality, 
morbidity, and HRQoL in NAFLD and NASH? 
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Methods  
This systematic review was conducted and reported in accordance with the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement.11 
The review was registered with PROSPERO - International prospective register of 
systematic reviews (CRD42019121054). 
 
Identification of studies and searches 
A detailed search strategy used both Indexing languages (e.g. MeSH and EmTree) 
and free text terms for NAFLD or NASH. These terms were combined with a second 
set of terms (for fibrosis) and liver-related clinical events or patient-related outcomes. 
A copy of the search strategy is available (e-Appendix 1). The following electronic 
databases were searched up to August 2018 by an experienced information 
specialist (SB): MEDLINE (Ovid), EMBASE (Ovid), Cochrane Library (Wiley), as 
were the trial registers - ClinicalTrials.gov, WHO ICTRP including ISRCTN and EU 
Clinical Trials Register. The search results were combined into an Endnote v.9 
database to facilitate reference management. The reference lists of all eligible 
studies and identified systematic reviews were checked for additional studies.  
 
Study selection 
Studies were included in this review if they met the following criteria: 
• Study design: prospective or retrospective cohort studies; RCTs or non-RCTs.  
• Population: adult (≥18 years) patients with biopsy proven NAFLD with or 
without the presence of NASH 
• Exposure: biopsy-confirmed liver fibrosis stage 
• Outcomes: all-cause and liver-related mortality; liver-related morbidity; and 
HRQoL  
In order to fully data extract and quality assess studies, we excluded studies only 
available as abstracts (authors were contacted to clarify the availability of full 
publication). We restricted inclusion to English language papers. We excluded 
studies reporting non-invasive indices of liver fibrosis (e.g. fibrosis-4 index, NAFLD 
fibrosis score). 
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Data extraction and risk of bias assessment  
The following information was extracted from included studies: study design, 
participants’ characteristics (i.e. number of patients with NAFLD, NASH and by 
fibrosis stage, and key confounders (see below)), method of NAFLD and NASH 
diagnosis and liver fibrosis assessment, final outcomes reported, length of follow-up, 
and outcome results.  
Study risk of bias was assessed through use of the QUIPS (QUality In Prognosis 
Studies) tool.12 This prognostic risk of bias tool was adapted to suit the requirements 
of this review (e-Appendix 2). The tool has six domains: 
1. Study participation 
2. Study attrition 
3. Prognostic factor measurement 
4. Outcome measurement 
5. Study confounding (research team clinicians (PNN, SMc) determined the key 
confounders: age, gender, diabetes mellitus, hypertension, statin use and 
smoking at cohort baseline)  
6. Statistical analysis and reporting. 
For each domain, the adequacy of reporting by a study was assessed as ‘yes’, 
‘partly’, or ‘no’. Based on domain assessments, studies were assigned to the 
following overall categories of risk of bias: 
• Low risk of bias: describes studies for which all domains are scored as ‘yes’; 
• Moderate risk of bias: describes studies for which one or more domains are 
scored as partly or one domain is scored as ‘no’; 
• High risk of bias: describes studies for which more than one domain is scored 
as ‘no’. 
The rating of the overall quality of the evidence from this review was undertaken in 
consideration of current guidance on the use of the GRADE (Grading of 
Recommendations, Assessment, Development and Evaluations) approach applied to 
prognostic studies.13  
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Statistical analysis 
Data were analysed in accordance with the Cochrane Handbook for Systematic 
Reviews of Interventions.14 We extracted the number of patients who experienced 
mortality (all-cause and liver-related), morbidity (cirrhosis, liver cancer, and all liver-
related events) by stage of fibrosis for all patients with NAFLD. In addition, the 
number of events were also extracted separately in two groups of NAFLD patients: 
(1) those reported to have NASH and (2) those reported not to have NASH. Using 
fibrosis stage 0 as a reference population, fibrosis stage-specific relative risk (RR) 
and 95% confidence interval (CI) for mortality and morbidity outcomes were 
estimated within the study – a RR > 1.00 indicated an increased risk of outcome with 
increasing fibrosis stage.  
Whilst this ‘crude’ (or ‘unadjusted’) RR compares risk by stage of liver fibrosis, it 
does not consider the potential variability in the duration of follow-up between studies 
and potential differences in patient characteristics between each of the fibrosis strata 
which could confound the comparison. We, therefore, also sought to identify the 
hazard ratios (HRs) (and their standard error) for change in fibrosis stage adjusted 
for confounders.  
Using fibrosis stage 0 as reference, the continuous outcome of HRQoL was 
extracted as a mean and standard deviation (or equivalent) for each fibrosis stage. 
Where not reported in publications, authors were contacted for summary outcome 
data.  
Where data was appropriately reported, we sought to undertake meta-analysis. 
Statistical heterogeneity between studies was assessed using the Chi2 test of 
heterogeneity and the Cochrane I2 statistic cut-offs, i.e. 0% to 40%: heterogeneity 
might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 
90%: may represent substantial heterogeneity; and 75% to 100%: considerable 
heterogeneity.14 When pooling the results across studies, we employed a random-
effects meta-analysis model where there was formal evidence of statistical 
heterogeneity (i.e. Chi2 test p-value<0.10 and substantial heterogeneity as defined 
by an I2 statistic ≥50%). For outcomes with lower levels of statistical heterogeneity, 
we applied both fixed-effect and random-effect models and reported where there 
was a discrepancy in model finding. Where there was an adequate number of 
studies (≥7 studies)14 small-study effects and publication bias were assessed using 
the funnel plot asymmetry and the Egger test.15 
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Meta-regression was used to examine the association between the pre-defined study 
level variables: study design (prospective vs retrospective cohort), overall risk of bias 
(medium or high), and mean duration of follow up (in years). This regression analysis 
was limited to those outcomes for which there was contributing data from ≥5 
studies.14 If there were suitable data (i.e. RCTs reporting change in fibrosis stage 
and outcomes of interest: mortality, liver-related morbidity and HRQoL) we planned 
to calculate and report two key indicators of surrogate endpoint validation.16 Firstly, 
we would calculate correlation coefficient and the R2 for the trial-level relationship 
between intervention-control differences in fibrosis and each of the final outcomes 
using weighting by the inverse of the variance (for the treatment effect on final 
outcomes). Secondly, from the trial-based analysis, we would estimate the surrogate 
threshold effect, i.e. the intercept of the prediction band of the regression line with 
zero effect on the final outcome.17 
All data analyses were conducted using Stata version 16.0 (Stata Corp., College 
Station, Texas) software. 
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Results 
Study selection 
After de-duplication, our database searches identified a total of 6,083 titles/abstracts. 
A further 210 study titles were identified from trial registers. Following review of all 
titles and full study publications, a total of 13 studies (15 publications) were judged to 
meet the inclusion criteria for this review.3,18-31 The study selection process is 
summarised in the flow diagram in Figure 1. Citations and reasons for studies 
excluded on review of full publication are listed in e-Appendix 3.  
 
Study and patient characteristics 
The included 13 studies recruited a total of 4,428 patients with biopsy confirmed 
NAFLD and subgroup of patients 2,875 (65%) had a histological proven diagnosis of 
NASH. Trial and study characteristics are presented in Table 1. Twelve were 
observational cohort studies (seven retrospective, five prospective) and one was a 
RCT. The median average age across studies was 51.0 years and 51% were male. 
Populations were multimorbid with a high prevalence of hypertension (median 
41.6%), diabetes mellitus (median 47.8%), treatment with statins (median 24.0 %), 
and overweight (median average body mass index (BMI) of 31.3 kg/m2). Fibrosis 
staging was confirmed by liver biopsy and centrally assessed in the majority of multi-
centre studies. The distribution of NAFLD patients by fibrosis stage was:  stage 0 - 
1,040 (23%); stage 1 - 1,094 (25%); stage 2 - 602 (14%); stage 3 - 922 (21%); stage 
4 - 770 (17%). Bhala et al (2011)18 and Vilar-Gomez (2018)29 included only patients 
with stage 3 and 4 and were therefore not includable in meta-analyses.  
The method of NASH diagnosis was poorly described but was judged to be 
adequately defined in seven studies.20,22,23,24,25,28,30 The two most common 
diagnostic metrics were fatty liver inhibition (FLIP) criteria or NASH Clinical Research 
Network (CRN) (i.e., presence of steatosis, ballooning and lobular inflammation). 
The median average duration of study follow up was 6.2 years, ranging from seven 
months to 19.9 years.  
  
Risk of bias assessment  
All studies were judged to have a moderate risk of bias with the exception of Leung 
et al (2017)24 which was deemed to be at high risk of bias and Vilar-Gomez (2018)29 
judged to be at low risk of bias (see Table 2). The QUIPS criteria of study population, 
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prognostic factor measurement and outcome measurement were generally well met 
(‘yes’ or ‘partly’), however, there was limited consideration of criteria of attrition, 
confounding measurement, and data analysis. Only Bhala et al (2011)18 and Vilar-
Gomez (2018)29 provided a sufficiently detailed description of loss to follow-up to 
assess risk of attrition, while the studies of Leung et al (2017)24 and Younossi et al 
(2018)30 provided no information on loss to follow-up. Angulo et al (2015)3 and Vilar-
Gomez (2018)29 were the only studies to report all key confounders (i.e., age, 
gender, diabetes mellitus, hypertension, statin use and smoking) and adjust for them 
all in their data analysis. Leung et al (2017)24 failed to report either how confounders 
were taken into account or how they were included in their data analysis.  
 
Outcomes 
Fibrosis stage outcomes in all patients with NAFLD without adjustment for covariates 
Across the ten studies reporting clinical events, a total of 591 out of 3,338 (17.7%) 
patients with NAFLD died over the period of follow-up, eight studies reported 95 
liver-related deaths in 2,729 patients (3.5%). Seven studies reported 52 out of 2,510 
(2.1%) NAFLD patients experienced a liver transplantation. Events due to liver 
morbidity were reported in 362 out of 3,125 patients (11.5%) across 8 studies based 
on combinations of events, that included liver failure, ascites, encephalopathy, and 
liver cancer. Meta-analysis showed that, compared to patients with NAFLD and no 
fibrosis (stage 0), patients with fibrosis were at an increased unadjusted RR of all-
cause mortality, liver-related mortality, liver transplantation, and all event liver 
morbidity  and this risk was incremental according to fibrosis stage (see Table 3, 
Figures 2 & 3). No statistical heterogeneity (I2 = 0%) was observed for the 
comparison of fibrosis stages 1-4 versus stage 0 across the four event outcomes. 
 
Fibrosis related event outcomes in all patients with NAFLD after adjustment for 
confounding covariates  
A sub-group of six studies provided hazard ratios for events comparing mild to 
moderate fibrosis (stages 0 to 2) to advanced fibrosis (stage 3 to 4) based on 
multivariable Cox regression models that adjusted for potential key confounding 
covariates.21,23-25,26,27,29 All studies adjusted their analyses for age, gender, diabetes 
and hypertension with exception of Seko et al (2015)27 that adjusted for age, gender, 
diabetes, and statin use. No studies included adjustment for both smoking and statin 
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use. Although not all studies reported data on event outcomes, there was a clear 
incremental risk with advanced fibrosis across all event outcomes as shown by a 
pooled hazard ratio of >1.0 (see e-appendix 4). In those studies that provided both 
an adjusted and unadjusted risk ratio, the magnitude of increased risk with advanced 
fibrosis appeared to similar as indicated by overlapping 95% confidence intervals. 
These conclusions remained consistent when Seko et al (2015) was removed from 
the meta-analysis.   
 
Impact of the presence of NASH on fibrosis related event outcomes without 
adjustment for covariates   
Four studies reported fibrosis related event outcomes in a cohort of NAFLD patients 
reported to have either NASH or not have NASH.20,23,24,25 A low level of statistical 
heterogeneity (I2 = 0%) was seen with the exception of liver transplantation events 
for stage 0 vs 4 in the subgroup without NASH where there was evidence of 
substantial heterogeneity (I2 = 56%) and pooled using a random effects meta-
analysis (see Table 4).  
There was an increase in the unadjusted risk of events with increasing stage of 
fibrosis for patients with NAFLD irrespective of the presence of NASH. The 
magnitude of increasing unadjusted risk appeared similar between patients with 
NAFLD with/without reported NASH, with overlapping 95% confidence of RR 
estimates (see Table 4 and e-Appendix 5).  
 
Fibrosis related HRQoL outcomes  
Three studies (1,089 NAFLD and 718 NASH patients) reported HRQoL using either 
the generic measure of SF-36 or the liver-specific measure of the Chronic Liver 
Disease Questionnaire (CLDQ). Given the heterogeneity of outcomes (generic 
instruments and liver-specific instrument but no NASH specific instrument), meta-
analysis was not deemed appropriate and instead numeric results were summarised 
across individual studies (see e-Appendix 6).  
The cross-sectional analysis of David et al (2009)19 used the generic Short Form-36 
to report that in a total of 713 NAFLD patients, those with stage 4 fibrosis (‘cirrhosis’) 
had significantly (p<0.001) worse physical health as assessed by SF-36 Physical 
Component Score (PCS) compared with patients with NAFLD and fibrosis stages 0-3 
(median 37 vs. median 47-50, p<0.001). This finding remained after adjustment for 
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potential confounders (i.e. age, sex, race, marital status, education, annual 
household income, BMI, type 2 diabetes). The study authors reported no significant 
difference across fibrosis stage for SF-36 Mental Component Score (MCS) (data not 
reported). Those with NASH reported significantly poorer physical health compared 
with those with no NASH (median 22.5 vs. 47.1, p<0.02). 
The prospective cohort of Huber et al (2018)22 found no difference in unadjusted total 
CLDQ score comparing a total of 304 patients with NAFLD stage 3-4 and stage 0-2 
fibrosis (mean 4.9, SD 1.2 vs. 5.1, SD 1.3; p=0.07). NASH was associated with a 
significant lower HRQoL compared to patients with NAFL (mean: 4.85, SD: 1.3 vs. 
5.31, 1.1, p<0.01). 
In an RCT with 72 NASH patients, Younossi et al (2018)31 found no difference in 
unadjusted baseline HRQoL between stage 2 and 3 fibrosis in either SF-36 (PCS - 
mean 45.0, SD 9.6 vs. 43.4, 10.3 & MCS - 51.0, 9.6 vs. 50.6, 12.7, both p>0.05) or 
total CLDQ score (mean 4.83, SD 1.10 vs. 4.91, 1.25, p>0.05).30 
 
Meta-regression 
Given the number of studies reporting clinical outcome data, we were able to 
undertake univariate meta-regression for RR analysis for all-cause mortality and all 
liver events for patients with NAFLD. There was no evidence of a differential effect of 
study level characteristics (i.e. study design, overall risk of bias or follow up) on the 
impact of stage of fibrosis for either of these outcomes (see e-Appendix 7).  
 
Small study bias  
We were able to assess small study bias for the relative outcomes of all-cause 
mortality and all liver events in patients with NAFLD. There was no formal evidence 
of funnel plot asymmetry except for all liver event for comparison of fibrosis stage 0 
vs 2 (Egger test, P=0.05) (see e-Appendix 8). This asymmetry appeared to be due to 
an absence of small- to medium-sized studies with a RR<1.0. 
 
Quality of evidence 
Based on the GRADE approach13 we found the quality of evidence for fibrosis in 
NAFLD as prognostic predictor of all-cause mortality to be high and for liver-mortality 
to be moderate (see e-Appendix 9). The quality of evidence for liver-related mortality. 
liver transplantation, and HRQoL for both NAFLD and NASH were all judged to be 
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low due to the sparse number of events or small number of studies. The outcome of 
all liver events was also judged to be of low quality because of inconsistency in its 
definition across studies. Given the smaller amount of evidence (studies and events), 
evidence quality for all outcomes for NASH was low.  
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Discussion 
This systematic review and meta-analysis identified a substantive and consistent 
body of international observational evidence that showed that stage of biopsy-
confirmed liver fibrosis is a strong predictor of future all-cause mortality and morbidity 
in NAFLD (with a five to 12 increase in relative risk of death and liver-related events 
including liver failure, transplantation, and liver cancer). Beyond the increased risk 
associated with fibrosis, the available data do not provide evidence for additional 
differential risk between the reported subgroups of NAFLD patients with NAFL or 
NASH. There was, however, limited and contradictory evidence of the impact of 
stage of fibrosis on the HRQoL, primarily due to the small number of studies, 
heterogeneity of the study subjects and lack of data from NASH-specific HRQoL 
instruments, such as CLDQ-NASH.32 
 
In context of current evidence  
This study demonstrates that both with and without adjustment for key potential 
confounding variables, biopsy-confirmed fibrosis is a key prognostic marker for all-
cause and liver related mortality in patients with NAFLD.8 The size and 
methodological rigour of this study now provides the confidence to support the 
conclusion of previous studies and recommendations of clinical guidelines. With 
advancing fibrosis, there is a stepwise increase in relative risk for liver morbidity, liver 
mortality and all-cause mortality.  
Our review also extends previous findings to the subset of patients who have 
reported histological evidence of NASH, showing that the risk of mortality and 
morbidity of increasing fibrosis stage appears be similar in magnitude to that seen for 
the whole cohort of patients with NAFLD, which includes patients categorised as 
currently having histological evidence of NASH or non-NASH. This is particularly 
important given the increasing focus of clinical trials on interventions on the inclusion 
of patients with NASH and the focus of these trials on a primary outcome that 
includes biopsy-confirmed fibrosis.33-35  
The United States FDA have recently published a table of surrogate endpoints that 
have either been already used in their development programs for drugs that have 
been approved, or surrogate endpoints that FDA has indicated acceptance of in their 
guidance or other documents.36,37 The FDA table of surrogate endpoints currently 
lists an ‘improvement of fibrosis with no worsening of steatohepatitis’ as a surrogate 
P a g e  | 19 
 
endpoint for clinical trials in NASH. Notably, our review did not identify strong 
evidence from RCTs that have reported an association between treatment-related 
improvement of stage of fibrosis and mortality, morbidity or HRQoL. Therefore, 
currently there appears to be no direct scientific evidence to validate fibrosis 
improvement as an established and validated surrogate endpoint of long-term 
outcomes. Whilst surrogacy of fibrosis is biologically plausible and stage of fibrosis is 
a strong prognostic marker, making fibrosis improvement a reasonable endpoint for 
granting provisional regulatory approval, there is ultimately a need to generate robust 
data to support this based on regulatory treatment trials in this field. This is important 
as regulatory bodies and payers, who are responsible for healthcare reimbursement 
decisions and typically more stringent in their evidence requirements, prefer 
evidence from final patient-relevant outcomes and will only accept surrogate 
endpoints if based on formal evidence of validation.5,6 The importance of the link 
between putative surrogates to clinically meaningful outcomes is recognised in the 
recent publication from an international workshop on clinical trial endpoints.38  
 
Strengths and limitations 
We believe this to be the most contemporary, comprehensive, and methodologically 
robust assessment of the literature to date, including 4,428 NAFLD patients and 591 
all-cause deaths. In contrast, the systematic review and meta-analysis of Dulai et al 
20178 included 1,495 NAFLD patients and 348 deaths. We extended the scope of 
this previous study to consider: the potential impact of key confounder variables, the 
subgroup of NAFLD patients with NASH, impact on liver-related morbidity and 
patient HRQoL, and the evidence base for change in stage of fibrosis as surrogate 
endpoint. Eleven out of 13 research teams of the included studies provided 
additional quantitative outcome data (not reported in their original published papers). 
As a result, we were able to ensure the inclusiveness of our meta-analysis. The 
comprehensiveness of data capture is supported by our finding of little or no 
publication bias. 
However, we recognise that our review has some limitations that largely reflect the 
nature and reporting of included studies. First, our primary analysis (and where we 
had most available data) i.e. estimation of pooled relative risk, was based on a 
simple comparison of the risk of outcomes in patients according to their stage of 
fibrosis (fibrosis stage 0 as reference). Given the fact that the demographic and 
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clinical characteristics of patients (e.g. age, gender, diabetes status) for the fibrosis 
stage categories is likely to be different, this crude (or ‘unadjusted’) analysis of RRs 
is likely to be prone to confounding. However, our adjusted analysis showed that the 
magnitude of outcome risk with increased fibrosis stage (fibrosis stage 0-2 vs. 3-4) 
was similar when compared to the results of the simple (unadjusted) pooled RR 
approach to pooling studies using hazard ratios and following adjustment for 
potential key confounders. Secondly, whilst we sought to extend our review to 
include data on NASH, included studies often did not provide a clear definition or 
explanation of how NASH was diagnosed. Differential diagnosis of NAFLD and 
NASH is a well-recognised controversy of current clinical practice.37 In order to make 
our findings as robust as possible, we limited our meta-analysis to the subgroup of 
studies that had a clear definition of NASH, such as the FLIP or NASH CRN score. 
However, even when selecting studies with a clear definition of NASH, we recognise 
that some patients with NASH (steatosis, ballooning and lobular inflammation) may 
be miscategorised as not having NASH because of sampling error on the biopsy. 
Moreover, a liver biopsy only represents a single point in time and steatohepatitis 
may fluctuating over time due to complex gene-environment interactions and in 
response to weight loss. Furthermore, as fibrosis progresses towards cirrhosis some 
features of NASH, such as steatosis and hepatocyte ballooning, may become less 
prominent and thus a patient may be categorised as not having ‘active’ NASH, yet 
NASH was clearly the causative factor in their liver fibrosis. Thirdly, studies reported 
liver-related morbidity based on differing combinations of liver-related clinical events. 
Therefore, there is a need for caution in the interpretation of the meta-analysis 
pooling of this composite outcome across studies. Fourthly, whilst we sought to 
include a range of clinical outcomes, the wide meta-analysis confidence intervals for 
some fibrosis stage outcome comparisons indicate the relatively sparse number of 
events available, especially liver transplantation. However, we also found no 
evidence of publication bias. Finally, included studies were of mixed methodological 
quality – seven out of 13 studies were retrospective in design and three were overall 
judged to be at high risk of bias. Nevertheless, our meta-regression analysis showed 
that our findings were insensitive to either study design or overall study risk of bias.   
Our review has identified several important areas for future research. (1) We need to 
better understand the association between fibrosis stage and patient reported well-
being. Future outcome NAFLD and NASH studies therefore need to consistently 
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collect patient HRQoL using generic (such as EQ-5D-5L) and disease-specific 
measures (such as CLDQ-NASH32). (2) Formal scientific validation of fibrosis as an 
acceptable surrogate endpoint is needed. Accepted statistical methods for surrogate 
validation include demonstration of a surrogate-final outcome association based on 
patient level data from a single RCT or from meta-analyses of multiple RCTs.16,40,41 
This evidence need is being addressed through long-term follow-up capturing hard 
clinical outcomes in all NASH Phase 3 trials that are currently recruiting (e.g. 
REGENERATE, REVERSE, RESOLVE-IT, AURORA).42-45 (3) Biopsy is an invasive 
procedure that limits clinical applicability in routine screening for NASH and there is a 
need therefore to investigate the suitability of other non-invasive alternative 
biomarkers as prognostic markers or validated surrogate endpoints, an issue that is 
currently being explored by two large international multi-stakeholder consortia in 
Europe (IMI2 LITMUS) and the USA (FNIH NIMBLE).46,47  
 
In conclusion, our study shows that with and without adjustment of key confounders, 
biopsy-confirmed fibrosis is a key prognostic marker of both mortality and liver-
related morbidity in NAFLD and the subgroups of NAFLD patients with and without 
reported NASH; increasing fibrosis stage being associated with a five to 12-fold 
increase in the relative risk of liver-related events. Further evidence from well 
reported studies is needed in order to clarify the impact of fibrosis stage on patient 
well-being (including NASH-specific HRQoL instruments), and to confirm change in 
biopsy-confirmed fibrosis as a valid surrogate endpoint in the context of RCTs of 
treatments for NAFLD and NASH. 
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FIGURE LEGENDS 
Figure 1. Summary of study selection process 
Figure 2.  Meta-analysis: Unadjusted relative risk of all-cause mortality by fibrosis 
stage (vs. stage 0) in all NAFLD patients  
Figure 3.  Meta-analysis: Unadjusted relative risk of liver events by fibrosis stage (vs. 
stage 0) in all NAFLD patients 
 
Table 1. Characteristics of included studies. 
Author (year) 
Country 
 
Study design 
Time period 
Sampling frame 
Population 
diagnosis  
 
Population 
demographics 
Fibrosis 
staging 
Outcomes 
reported 
Follow up  
Angulo (2015) 
 
Australia, 
Denmark, Iceland, 
Thailand, UK, US 
 
NR centres 
Retrospective 
cohort study 
 
1975-20052 
 
Consecutive 
patients 
619 patients with 
liver biopsy 
confirmed NAFLD 
 
284 with NASH, 
method of 
confirmation not 
reported 
Age: median 49  
DM: 37.5% 
White: 88% 
Male: 37.5% 
HTN: 30.7% 
Statin use: 63% 
Smoking: 8.7% 
Biopsy centrally 
confirmed and 
reported as stage 
0-4 
Overall mortality, 
Liver 
transplantation, 
Liver events1 
 
Median 12.6 yrs 
(range 0.3-35.1) 
Bhala (2011) 
 
Australia, Italy, 
UK, USA, 
Thailand 
 
4 centres 
Prospective cohort 
study 
 
1984-20062 
 
Consecutive 
patients 
247 patients with 
liver biopsy 
confirmed NAFLD 
with advanced 
fibrosis or 
cirrhosis 
 
247 with NASH, 
all with advanced 
fibrosis or 
cirrhosis 
Age: mean 55 
DM: 50.6%  
White: 91.5% 
Male: 39.5% 
HTN: 44.1% 
Statin use: 21.5% 
Smoking: Not 
reported 
Biopsy reviewed 
independently and 
reported as stage 
3 & 4 
Overall mortality, 
Liver-related 
mortality, Overall 
vascular events, 
Myocardial 
infarction, 
Total liver events3, 
Varices, Ascites, 
Encephalopathy 
Mean: 7.1 yrs 
(range: 0.5-24.75) 
David (2009) 
 
US  
Cross-sectional 
study (based on 
NAFLD 
713 patients with 
liver biopsy 
confirmed NAFLD 
Age: mean 48 
DM: not reported 
White: 76.2% 
Biopsy centrally 
confirmed and 
reported as stage 
Health-related 
quality of life (SF-
36) 
Not applicable  
(NASH CRN 
Research Group) 
 
8 centres 
prospective cohort 
& PIVENS RCT) 
 
2004-20072 
 
Not reported 
 
436 with NASH, 
method of 
confirmation not 
reported 
Male: 37.7% 
HTN: 27% 
Statin use: not 
reported 
Smoking: not 
reported 
0-4 
Hagstrom 
(2017i,ii) 
 
Sweden  
 
2 centres 
Retrospective 
cohort study 
 
1971-20094 
 
All patients 
646 patients with 
liver biopsy 
confirmed NAFLD 
 
383 with NASH, 
defined by fatty 
liver inhibition of 
progression 
(FLIP) algorithm 
Age: mean 48 
DM: 14.4%  
White: not reported  
Male: 62.2% 
HTN: 30.3%  
Statin use: not 
reported 
Smoking: 24.0% 
Biopsy centrally 
confirmed and 
reported as stage 
0-4 
Overall mortality, 
Severe liver 
disease5 
Mean: 19.9 yrs 
(range: 0.4-40) 
Huber (2018) 
 
Germany, Spain, 
UK  
(European NAFLD 
registry) 
 
3 centres 
Prospective cohort 
study 
 
Not reported 
 
Not reported 
304 patients with 
liver biopsy 
confirmed NAFLD 
 
210 with NASH, 
defined by the 
presence of 
steatosis, 
ballooning and 
lobular 
inflammation 
Age: median 54 
DM: 51.3% [T2] 
White: not reported 
Male: 53.3% 
HTN: 66.8% 
Statin use: not 
reported 
Smoking: not 
reported 
Biopsy centrally 
confirmed and 
reported as stage 
0-4 
Health-related 
quality of life  
Chronic Liver 
Disease 
Questionnaire 
(CLDQ) 
Up to 6-months 
post biopsy 
Ito (2019) 
 
Japan 
 
2 centres 
Retrospective 
cohort study 
 
1999-20145 
 
All patients 
246 patients with 
liver biopsy 
confirmed NAFLD 
 
156 with NASH, 
defined by FLIP 
criteria 
 
Age: median 55 
DM: 45.1% 
White: not reported 
Male: 52% 
HTN: 41.6% 
Statin use: no 
reported 
Smoking: not 
reported 
Biopsy centrally 
confirmed and 
reported as stage 
0-4 
Overall mortality, 
Liver cirrhosis, 
Liver cancer, 
extra-hepatic 
cancer, 
cardiovascular 
disease 
Median: 7.0 yrs 
(range 4.4-10.0) 
Leung (2017) 
 
Hong Kong 
 
1 centre 
Prospective cohort 
study 
 
2006-20156 
 
Consecutive 
patients 
300^ patients with 
liver biopsy 
confirmed NAFLD 
 
151 with NASH, 
defined by FLIP 
criteria 
 
Age: mean 51 
DM: 55.4% 
White: not reported  
Male: 55.7% 
HTN: 55.4% 
Statin use: not 
reported 
Smoking: not 
reported 
Biopsy centrally 
confirmed and 
reported as stage 
0-4 
Overall mortality, 
liver-related 
events7, non-
hepatic cancer, 
cardiovascular 
disease 
Median: 4.1 yrs 
(range NR) 
Peleg (2018) 
 
Israel 
 
1 centre 
 
Retrospective 
cohort study 
 
2005-20126 
 
All patients 
153 patients with 
liver biopsy 
confirmed NAFLD 
 
27 with NASH, 
defined by the 
presence of 
steatosis, 
ballooning and 
Age: mean 49.5 
DM: 63.4% [T] 
White: not reported 
Male: 55.5% 
HTN: 41.1% 
Statin use: 53.8% 
Smoking: not 
reported 
Biopsy confirmed 
and reported as 
stage 0-4 
Overall mortality, 
malignancies, liver 
events8, hospital 
admissions 
Mean: 8.3 yrs 
(range 5.1-12.0) 
lobular 
inflammation 
Sebastiani (2015) 
 
Canada 
 
Single centre  
Retrospective 
cohort study 
 
2004-20139 
 
Consecutive 
patients 
148 patients with 
liver biopsy 
confirmed 
NAFLD,  
 
148 with NASH, 
definition not 
specified 
 
Age: mean 49.5 
DM: 33.1% 
White: not reported  
Male: 69.6% 
HTN: 39.2% 
Statin use: not 
reported 
Smoking: no 
reported 
Biopsy confirmed 
and reported as 
stage 0-4 
Clinical 
outcomes10 
Median: 5 yrs 
(interquartile 
range: 3-8) 
Seko (2015) 
 
Japan  
 
1 centre 
Retrospective 
cohort study 
 
1999-20136 
 
All patients 
312 patients with 
liver biopsy 
confirmed NAFLD 
 
176 with NASH, 
defined by 
Younossi criteria 
Age: median 59 
DM: 35%  
White: not reported 
Male: 51% 
HTN: not reported 
Statin use: 40.3% 
Smoking: not 
reported 
Biopsy confirmed 
and reported as 
stage 0-4 
Overall mortality, 
malignancies 
Median: 4.8 yrs 
(0.3-15.7) 
Vilar-Gomez 
(2018) 
 
Australia, Cuba, 
Hong Kong, Spain 
 
5 centres 
Prospective cohort 
study 
 
1995-201611 
 
Consecutive 
patients 
458 patients with 
liver biopsy 
confirmed NAFLD 
 
458 with assumed 
to be NASH by 
nature of stage 3-
Age: mean 55.9 
DM: 67%  
White: 81% 
Male: 48% 
HTN: 61% 
Statin use: 24% 
Smoking: 17% 
Biopsy reviewed 
independently and 
reported as stage 
3 & 4 
Overall mortality, 
major clinical 
events12 
Mean: 5.5 yrs  
(2.7-8.2) 
4 fibrosis 
 
Younossi 
(2011/17) 
 
USA 
 
3 centres 
Retrospective 
cohort study 
 
Not reported  
 
Not reported 
210+ patients with 
liver biopsy 
confirmed NAFLD 
 
131 with NASH, 
defined by the 
presence of 
steatosis, 
ballooning and 
lobular 
inflammation 
Age: mean 49* 
DM: 20.5% [T2]  
White: not reported  
Male: 37.8% 
HTN: not reported 
Statin use: not 
reported 
Smoking: not 
reported 
Biopsy confirmed, 
NAS and Brunt 0-
4 fibrosis  
 
Liver-related 
mortality 
Median: 12.1 yrs 
(interquartile 
range: 4.9-15.5) 
Younossi (2018) 
 
USA/Canada 
 
23 centres 
Randomised 
controlled trial 
 
2015-201711 
 
Not reported 
 
 
72 patients with 
liver biopsy 
confirmed NAFLD 
 
72 with NASH, 
defined by the 
presence of 
steatosis, 
ballooning and 
lobular 
inflammation 
Age: mean 54 
DM: 70.8%  
White: 90.3% 
Male: 30.6% 
HTN: 66.7% 
Statin use: not 
reported 
Smoking: not 
reported 
Biopsy confirmed 
stage 2-3 
fibrosis 
Health-related 
quality of life (SF-
36 & Chronic Liver 
Disease 
Questionnaire 
(CLDQ))  
Up to 24 weeks 
Footnotes: 
1. Gastroesophageal varices/bleeding, ascites, portosystemic encephalopathy, spontaneous bacterial peritonitis, hepatocellular cancer, hepatopulmonary syndrome, 
hepatorenal syndrome 
2. Year of recruitment  
3. Liver failure, gastroesophageal varices, ascites, encephalopathy, hepatopulmonary syndrome, HCC 
4. Year of diagnosis 
5. Acute and subacute liver failure, ascites, oesophageal varices, hepatorenal syndrome, chronic liver failure, cirrhosis NUD, hepatic encephalopathy, liver failure NUD, portal 
hypertension, hepatocellular carcinoma 
6. Year of biopsy 
7. Hepatocellular carcinoma, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, variceal bleeding, hepatic encephalopathy, liver transplantation 
8. Oesophageal varices, hepatic encephalopathy, ascites and TIPS. 
9. Year of study visits 
10. Death, liver transplantation, cirrhosis complications 
11. Years of study 
*: weighted mean; +: based on number reported in Dulai et al 2017 review [8]; ^: 307 patients reported in paper but data provided by research groups included only 300 
Abbreviations: BMI – body mass index; CRN – NASH Clinical Research Network; DM – diabetes mellitus; FLIP: fatty liver inhibition of progression; HTN; hypertension NAFLD – Non-
alcoholic fatty liver disease; NASH; NR – not reported;  
 
 
  
Table 2. Assessment of risk of bias of included studies - based on QUIPs tool.  
Author (year) 
Country 
 
Study 
Population 
Study 
Attrition  
Prognostic 
factor 
measurement 
Outcome 
measurement 
Confounding 
assessment 
& account 
Data 
analysis & 
reporting 
Overall 
assessment* 
Angulo (2015) 
 
Yes Partly  Yes Partly Yes Yes Moderate risk 
of bias 
Bhala (2011) 
 
 
Yes Yes Yes Yes Yes Partly  Moderate risk 
of bias 
David (2009) 
 
 
Partly No Yes Yes Partly Partly Moderate risk 
of bias 
Hagstrom 
(2017i,ii) 
 
Yes Partly Yes Yes Partly Partly Moderate risk 
of bias 
Huber (2018) 
 
Partly No Yes Yes Partly Partly Moderate risk 
of bias 
Ito (2019) 
 
Yes Partly Yes Yes Partly Partly Moderate risk 
of bias 
Leung (2017) 
 
Yes  Partly Partly Yes No No High risk of 
bias 
Peleg (2018) 
 
Yes Partly Yes Yes Partly Partly Moderate risk 
of bias 
Sebastiani Yes Partly Yes Yes Partly Partly Moderate risk 
(2015) 
  
of bias 
Seko (2015) 
 
No  Partly Partly Partly Partly Partly Moderate risk 
of bias 
Vilar-Gomez 
(2018) 
Yes Yes Yes Yes Yes Yes Low risk of 
bias 
Younossi 
(2011/17) 
 
Partly Partly Yes Yes Partly No Moderate risk 
of bias 
Younossi (2018) 
 
Partly Yes Yes Yes Yes No Moderate risk 
of bias 
*Low risk of bias: describes studies for which all domains are scored as “yes”; Moderate risk of bias: describes studies for which one 
or more domains are scored as partly or one domain is scored as “no”; High risk of bias: describes studies for which more than one 
domain is scored as “no”. 
 
  
Table 3. Meta-analysis: Pooled unadjusted relative risk by fibrosis stage (relative to stage 0) for all patients with 
NAFLD  
 
Stage 0 versus 1 
Relative Risk (95% CI), 
P-value 
n/N vs n/N, I2 statistic 
Stage 0 versus 2 
Relative Risk (95% CI), P-
value 
n/N vs n/N, I2 statistic 
Stage 0 versus 3 
Relative Risk (95% CI), P-
value 
n/N vs n/N, I2 statistic 
Stage 0 versus 4 
Relative Risk (95% CI), P-
value 
n/N vs n/N, I2 statistic 
All-cause mortality 
N=8 
studies 
1.12 (0.91 to 1.38) 
135/843 vs 136/896, 0% 
1.50 (1.20 to 1.86) 
135/843 vs 103/425, 0% 
2.13 (1.70 to 2.67) 
135/843 vs 86/301, 0% 
3.42 (2.63 to 4.46) 
135/843 vs 61/169, 27% 
Liver-related mortality 
N=7 
studies 
1.05 (0.35 to 3.16) 
3/521 vs 7/755, 0% 
2.53 (0.88 to 7.27) 
3/521 vs 10/340, 0% 
6.65 (1.99 to 22.25) 
3/521 vs 12/248, 0% 
11.13 (4.15 to 29.84),  0% 
3/521 vs 22/151 
Liver transplantation 
N=6 
studies 
0.40 (0.02 to 7.50) 
0/466 vs 2/691, 0% 
1.98 (0.24 to 16.10) 
0/466 vs 3/314, 0% 
RR not calculable 
0/466 vs 0/205, 0% 
5.42 (1.05 to 27.89) 
0/466 vs 6/129, 0% 
All liver events 
N=7 
studies 
1.02 (0.58 to 1.89) 
18/787 vs 25/823, 0% 
2.67 (1.58 to 4.51) 
19/787 vs 39/399, 0% 
5.24 (3.97 to 8.98) 
19/787 vs 39/256, 0%  
12.78 (6.85 to 23.85) 
19/787 vs 52/156, 0% 
All meta-analyses fixed effect  
  
Table 4. Stratified meta-analysis: Pooled unadjusted relative risk by fibrosis stage (relative to stage 0) for NAFLD 
patients with reported NASH versus NALFD patients with no reported NASH (N=4 studies) 
 
Stage 0 versus 1 
Relative Risk (95% CI), 
P-value 
n/N vs n/N, I2 statistic 
Stage 0 versus 2 
Relative Risk (95% CI), 
P-value 
n/N vs n/N, I2 statistic 
Stage 0 versus 3 
Relative Risk (95% CI), 
P-value 
n/N vs n/N, I2 statistic 
Stage 0 versus 4 
Relative Risk (95% CI), 
P-value 
n/N vs n/N, I2 statistic 
All-cause mortality 
NAFLD with 
NASH  
0.91 (0.54 to 1.51) 
13/83 vs 44/319, 0% 
1.24 (0.74 to 2.07) 
13/83 vs 47/202, 0% 
1.99 (1.17 to 3.41) 
13/83 vs 45/155, 0% 
3.26 (1.78 to 5.98) 
13/83 vs 31/90, 0% 
NAFLD without 
NASH 
1.15 (0.87 to 1.52) 
46/279 vs 49/294, 29% 
1.40 (0.85 to 2.28) 
46/279 vs 17/71, 0% 
2.60 (1.64 to 4.09) 
46/279 vs 11/38, 0% 
2.91 (1.08 to 7.87) 
46/279 vs 8/23, 0% 
Liver-related mortality 
NAFLD with 
NASH 
0.35 (0.07 to 1.77) 
2/83 vs 3/319, 0% 
0.78 (0.21 to 2.92) 
2/83 vs 6/201, 0% 
1.24 (0.31 to 4.93) 
2/83 vs 10/155, 0% 
3.74 (0.83 to 16.83) 
2/83 vs 13/90, 0% 
NAFLD without 
NASH 
1.10 (0.40 to 3.04) 
1/279 vs 3/291, 0% 
7.31 (0.68 to 78.10) 
1/279 vs 2/72, NA 
26.0 (2.60 to 260.04) 
1/279 vs 2/38, NA 
8.17 (1.27 to 52.58) 
1/279 vs 18/114, 0% 
Liver transplantation 
NAFLD with 
NASH 
RR not estimable 
0/62 vs 0/281, NA 
RR not estimable 
0/62 vs 0/176, NA 
RR not estimable 
0/62 vs 0/114, NA 
RR not estimable 
0/62 vs 1/69, NA 
NAFLD without 
NASH 
0.47 (0.02 to 8.79)  
0/245 vs 2/268, NA 
3.50 (0.52 to 23.69) 
0/245 vs 3/71, 0% 
RR not estimable 
0/245 vs 0/36, NA 
15.07 (0.63 to 359.22)* 
0/245 vs 3/23, 56% 
All liver events 
NAFLD with 
NASH  
0.47 (0.17 to 1.29) 
5/77 vs 9/281, 0% 
1.21 (0.51 to 2.91) 
5/77 vs 19/176, 0% 
2.16 (0.85 to 4.47) 
5/77 vs 17/114, 0% 
6.48 (2.89 to 14.85) 
5/77 vs 23/69, 0% 
NAFLD without 
NASH  
1.08 (0.45 to 2.58) 
8/230 vs 11/268, 0% 
2.85 (1.12 to 7.24) 
8/230 vs 11/71, 0% 
4.56 (1.64 to 12.60) 
8/230 vs 7/36, 0% 
9.80 (3.12 to 30.76) 
8/230 vs 15/28, 0% 
NA: not applicable; *: random effects meta-analyses. All other meta-analyses fixed effect 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Titles identified from searches 
of trial registries 
 
N = 210 
+ 
Titles identified from electronic 
bibliographies & screened for 
retrieval 
N = 6,083 
Potentially appropriate full-text 
publications retrieved for  
full evaluation 
N = 51 
Studies with data includable for 
meta-analysis  
N = 8  
(N = 9 publications) 
 
Excluded N = 37 
• Systematic review N = 5 
• Non-histological definition of liver fibrosis N = 11 
• Abstract N = 7 
• No fibrosis vs outcome analysis N = 10 
• Duplicate patient cohort N = 2 
• Cross-sectional design N =2 
 
Excluded 
N = 6,242 
Studies that meet in 
inclusion criteria  
N = 13  
(N = 15 publications) 
Identified from 
included studies  
N = 1 
Excluded N = 5 
• HRQoL only outcomes N = 3 
• no F0 patient N = 2 
 
 
  
 
Overall  (I-squared = 0.0%, p = 0.794)
Seko (2015)
Sebastiani (2015)
Study
Hagstrom (2017i,ii,iii)
Younossi (2011/17)
ID
Leung (2017)
Ito (2019)
Angulo (2015)
Peleg (2018)
1.12 (0.91, 1.38)
0.76 (0.07, 8.30)
(Excluded)
Relative
0.96 (0.70, 1.31)
1.20 (0.58, 2.49)
Risk (95% CI)
0.71 (0.10, 4.91)
4.43 (0.23, 84.28)
1.30 (0.94, 1.79)
0.56 (0.03, 9.74)
136/896
1/89
0/53
Events,
71/256
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Treatment
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47/163
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Control
2/77
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74/322
0/6
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Overall  (I-squared = 0.0%, p = 0.550)
Study
ID
Peleg (2018)
Ito (2019)
Younossi (2011/17)
Angulo (2015)
Sebastiani (2015)
Hagstrom (2017i,ii,iii)
Leung (2017)
Seko (2015)
1.50 (1.20, 1.86)
Relative
Risk (95% CI)
2.66 (0.17, 42.58)
4.77 (0.20, 114.16)
1.69 (0.76, 3.78)
1.84 (1.34, 2.53)
3.13 (0.13, 72.99)
1.16 (0.84, 1.62)
0.47 (0.02, 9.58)
3.02 (0.44, 20.84)
103/425
Events,
Treatment
5/28
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135/843
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Control
0/6
0/61
10/55
74/322
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47/163
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1.5 2 4 8
All Cause Mortality NAFLD stage 0 vs stage 2
Overall  (I-squared = 0.0%, p = 0.550)
Study
ID
Peleg (2018)
Ito (2019)
Younossi (2011/17)
Angulo (2015)
Sebastiani (2015)
Hagstrom (2017i,ii,iii)
Leung (2017)
Seko (2015)
1.50 (1.20, 1.86)
Relative
Risk (95% CI)
2.66 (0.17, 42.58)
4.77 (0.20, 114.16)
1.69 (0.76, 3.78)
1.84 (1.34, 2.53)
3.13 (0.13, 72.99)
1.16 (0.84, 1.62)
0.47 (0.02, 9.58)
3.02 (0.44, 20.84)
103/425
Events,
Treatment
5/28
1/38
8/26
36/85
1/22
50/149
0/32
2/45
135/843
Events,
Control
0/6
0/61
10/55
74/322
0/23
47/163
2/77
2/136
  
1.5 2 4 8
All Cause Mortality NAFLD stage 0 vs stage 2
Overall  (I-squared = 27.0%, p = 0.213)
Study
Angulo (2015)
Seko (2015)
Leung (2017)
Peleg (2018)
ID
Sebastiani (2015)
Ito (2019)
Younossi (2011/17)
Hagstrom (2017i,ii,iii)
3.42 (2.63, 4.46)
Relative
3.38 (2.46, 4.65)
13.60 (2.46, 75.04)
1.64 (0.24, 11.24)
6.61 (0.44, 99.88)
Risk (95% CI)
11.48 (0.67, 196.07)
34.44 (1.79, 661.25)
3.25 (1.68, 6.29)
2.43 (1.67, 3.53)
61/169
Events,
14/18
3/15
2/47
8/17
Treatment
5/22
2/8
13/22
14/20
135/843
Events,
74/322
2/136
2/77
0/6
Control
0/23
0/61
10/55
47/163
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veral  (I-squared = 0.0%, p = 0.877)
Seko (2015)
Hagstrom (2017i,ii,iii)
Sebastiani (2015)
Ito (2019)
ounossi (201 /17)
Leung (2017)
ID
Peleg (2018)
Angulo (2015)
Study
2.13 (1.70, .67)
0.98 (0.05, 19.83)
1.91 (1.37, 2.67)
5.79 (0.31, 106.71)
7.21 (0.35, 146.46)
2.43 (1.26, 4. 7)
0.43 (0.02, 8.80)
Risk (95% CI)
3.06 (0.18, 51.74)
2.22 (1.59, 3.09)
Relative
86/301
0/27
32/58
3/28
2/42
19/43
0/35
Treatment
3/15
27/53
Events,
135/843
2/136
47/163
0/23
0/61
10/55
2/77
Control
0/6
74/322
Events,
  
1.25 .5 2 4 8
All Cause Mortality NAFLD stage 0 vs stage 3
  
 
 
 
 
Overall  (I-squared = 0.0%, p = 0.702)
Sebastiani (2015)
Ito (2019)
Angulo (2015)
Hagstrom (2017i,ii,iii)
Peleg (2018)
Seko (2015)
Study
Leung (2017)
ID
1.02 (0.58, 1.80)
(Excluded)
1.90 (0.08, 45.86)
1.82 (0.50, 6.68)
0.85 (0.41, 1.75)
0.56 (0.03, 9.74)
4.57 (0.19, 110.87)
Relative
0.24 (0.01, 5.73)
Risk (95% CI)
25/832
0/53
1/97
4/141
16/256
3/87
1/89
Events,
0/109
Treatment
18/787
0/23
0/61
5/321
12/163
0/6
0/136
Events,
1/77
Control
  
1.25 .5 2 4 8
Liver events NAFLD stage 0 vs stage 1
Overall  (I-squared = 0.0%, p = 0.574)
Angulo (2015)
ID
Hagstrom (2017i,ii,iii)
Sebastiani (2015)
Leung (2017)
Ito (2019)
Study
Peleg (2018)
Seko (2015)
2.67 (1.58, 4.51)
4.53 (1.42, 14.49)
Risk (95% CI)
1.64 (0.82, 3.29)
5.22 (0.26, 102.93)
2.41 (0.16, 37.30)
14.31 (0.79, 258.51)
Relative
3.62 (0.23, 56.14)
8.93 (0.37, 215.53)
39/399
6/85
Treatment
18/149
2/22
1/32
4/38
Events,
7/28
1/45
18/787
5/321
Control
12/163
0/23
1/77
0/61
Events,
0/6
0/136
  
1.25 .5 2 4 8
Liver events NAFLD stage 0 vs stage 2
Overall  (I-squared = 0.0%, p = 0.450)
Peleg (2018)
Sebastiani (2015)
ID
Seko (2015)
Ito (2019)
Leung (2017)
Hagstrom (2017i,ii,iii)
Angulo (2015)
Study
5.24 (3.07, 8.96)
3.06 (0.18, 51.74)
10.76 (0.64, 181.42)
Risk (95% CI)
24.46 (1.21, 495.84)
18.74 (1.08, 324.05)
0.72 (0.03, 17.30)
3.51 (1.75, 7.06)
8.81 (2.91, 26.71)
Relative
39/256
3/15
6/28
Treatment
2/27
6/42
0/35
15/58
7/51
Events,
18/787
0/6
0/23
Control
0/136
0/61
1/77
12/163
5/321
Events,
  
1.25 .5 2 4 8
Liver events NAFLD stage 0 vs stage 3
Overall  (I-squared = 0.0%, p = 0.820)
Sebastiani (2015)
Study
Leung (2017)
ID
Seko (2015)
Peleg (2018)
Hagstrom (2017i,ii,iii)
Angulo (2015)
Ito (2019)
12.78 (6.85, 23.85)
21.91 (1.36, 352.79)
Relative
4.91 (0.53, 45.89)
Risk (95% CI)
42.81 (2.15, 852.96)
12.06 (0.83, 175.38)
10.19 (5.59, 18.57)
15.11 (4.46, 51.22)
48.22 (2.71, 858.64)
52/146
10/22
Events,
3/47
Treatment
2/15
15/17
15/20
4/17
3/8
18/787
0/23
Events,
1/77
Control
0/136
0/6
12/163
5/321
0/61
  
1.25 .5 2 4 8
Liver events NAFLD stage 0 vs stage 4
 
 
 
SUPPLEMENTAL MATERIAL  
eAppendix 1. Search strategy  
Database: Ovid MEDLINE(R) 1946 to October week 3 2018 
1     (NAFLD or NASH).mp. or non-alcoholic fatty liver.ti,ab. 
2     non-alcoholic steatohepatitis.ti,ab.  
3     Non-alcoholic Fatty Liver Disease/  
4     exp Fatty Liver/  
5     or/1-4  
6     fibrosis.ti,ab.  
7     fibrosis/  
8     cirrhosis or cirrhoses.ti,ab. 
9     or/6-8  
10     surrogate$.ti,ab.  
11     variceal bleed$.ti,ab. 
12     decompensat$.ti,ab.  
13     (scar$ adj2 liver$).ti,ab. 
14     ascites.ti,ab.  
15     outcome$.ti,ab.  
16     disease progress$.ti,ab, 
17     (patient adj3 outcome$) or PROM$.ti,ab 
18     ((liver) adj2 (cancer or transplant$ or carcinoma$ or failure)).ti,ab 
19     death$.mp. or mortality.ti,ab 
20     hepatocellular cancer.ti,ab.  
21     hepatic encephalopathy.ti,ab. 
22     hepatoencephalopathy.ti,ab.  
23     exp liver neoplasms/  
24     or/10-23  
25     5 and 9  
26     24 and 25  
27     (pre-clinical or rat or rats or mouse or mice or animal) or animals.ti,ab 
28     26 not 27 
eAppendix 2. QUIPS (QUality In Prognosis Studies) tool 
Potential bias (circle one) Items considered for assessment of potential opportunity for bias Yes response No response Study 1 Study 2 Study 3 Study 4 
Study Population 
 
The study sample represents the 
population on key characteristics 
sufficient to limit potential bias to 
the observed relationship between 
BMI and mortality 
The source population of interest is adequately described for key 
characteristics and the study setting supports the applicability of results. 
Eligibility criteria and recruitment are adequately described and the 
inclusion/ exclusion criteria applied uniformly to all screened for eligibility. 
There is adequate participation in the study by eligible individuals and 
sufficient information was given about those who did not participate. The 
baseline characteristics or participants included is adequately described 
for characteristics and representative of the population of interest.  
AKI adult (>18 yrs) patients AND AKI 
criterion reported (e.g. creatinine clearance 
+/- urine output, staging) AND patient 
characteristics include ethnicity, underlying 
condition AND no major exclusions AND 
treatment method for AKI (if applicable) 
described e.g. RRT, mechanical ventilation 
Non-adults included, patient 
characteristics not adequately 
described, underlying condition 
unknown/ not detailed, major 
exclusions involved and 
treatment method not detailed 
Yes Partly No 
Study Attrition 
 
Loss to follow-up (from sample to 
study population) is not associated 
with key characteristics (i.e. the 
study data represent the sample), 
sufficient to limit potential bias 
Attempts to collect information on participants who dropped out of the 
study are described. Reasons for loss to follow-up are provided. There are 
no important differences between key characteristics (e.g. ethnicity, 
underlying condition, age, treatment method) and outcomes in 
participants who completed the study and those who did not.  
Reasons lost to follow-up reported with 
numbers AND comparison of lost verses not 
lost to follow-up with no important 
differences, or if important differences 
found addressed in the analysis 
Attrition/ denominators not 
reported/ accounted for 
        
Yes Partly No 
Prognostic factor measurement 
 
BMI/ body mass is adequately 
measured in study participants to 
sufficiently limit bias 
Body mass measured at time of AKI presentation. Clear definition of BMI 
given and BMI category ranges provided with number of participants in 
each BMI category reported OR sufficient data provided to determine BMI 
categories. Adequate proportion of the study sample has complete data. 
Data collection is prospective and recorded 
on presentation of AKI AND  BMI criteria 
defined  
Definition of BMI not clear or 
sufficiently detailed (e.g. BMI > 
30 is categorised as obese with 
no other obese categories 
included or clear data on the 
range of BMIs > 30) 
        
Yes Partly No 
Outcome measurement Clear definition of mortality measurement provided, including duration of Mortality incidence recorded AND time- mortality incidence and         
Mortality incidence is adequately 
measured in study participants to 
sufficiently limit potential bias 
follow-up. Mortality risk measured prior to outcome occurring.  frame for mortality reported AND data 
collection for mortality risk is prospective   
timeframe for follow-up not 
reported  
Yes Partly No 
Confounding measurement and 
account 
 
 Important potential confounders 
are appropriately accounted for, 
limiting potential bias with respect 
to body mass 
Important potential confounders are accounted for in the study design 
(e.g. patients separated into different BMI categories if ethnic origin 
differs i.e. afro-Caribbean, south Asian) and analysis. Measurement of all 
important confounders is adequately valid and reliable (e.g. accounting for 
hydration status when measuring weight -- under-hydrated or fluid 
overloaded patients). The method and setting of confounding 
measurement are the same for all participants (e.g. same scales). 
Appropriate imputation method is used for missing confounder data. 
Appropriate adjustment used and clearly outlined. Interventions do not 
confound body mass results or mortality outcome. 
BMI categories adequately defined AND 
based on accurate, reliable weights. 
Adjusters, if used, are appropriate and 
clearly outlined. Intervention method does 
not impact on mortality outcome 
BMI or body mass 
measurements are not clearly or 
adequately defined. Validity of 
body mass measurements not 
reported on 
        
Yes Partly No 
Analysis and reporting There is sufficient presentation of data to assess the adequacy of the 
analysis. The selected statistical method of analysis is adequate for the 
design of the study (e.g. mortality incidence risk). There is no selective 
reporting of results. 
Statistical model used appropriate for the 
study design and type of data AND strategy 
and results clearly reported AND 
completeness of reporting of results  
Unclear reporting of strategy or 
results AND inappropriate 
statistical model AND selective 
reporting of results 
        
The statistical analysis is 
appropriate for the design of the 
study, limiting potential for 
presentation of invalid results 
Yes Partly No 
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Hepatology 2013;57:1357-1365. [NFD-score not liver biopsy] 
12. Le MH et al. Prevalence of non-alcoholic fatty liver disease and risk factors for 
advanced fibrosis and mortality in the United States. PLoS One. 
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29. Treeprasertsuk S et al. NAFLD fibrosis score: a prognostic predictor for 
mortality and liver complications among NAFLD patients. World J 
Gastroenterol. 2013;19:1219-1229. [non-invasive fibrosis score] 
30. Unalp-Arida A et al. Liver fibrosis scores predict liver disease mortality in the 
United States population. Hepatology 2017;66: 84-95. [non-invasive fibrosis 
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e-Appendix 4. Meta-analysis: Pooled hazard ratio (adjusted) and pooled relative risk (unadjusted) by fibrosis stage 0-2 vs 
2-4 for all patients with NAFLD  
 
Stage 0-2 versus 3-4 
Adjusted hazard ratio (95% CI) P-value, I2 statistic 
Stage 0-2 versus 3-4 
Unadjusted relative risk (95% CI) P-value, I2 statistic 
All-cause mortality 
  N=5 studies 2.24 (1.48 to 3.39), 31% 2.25 (1.85 to 2.72), 35% 
Liver-related mortality 
  N= 4 studies 5.12 (2.48 to 10.55), 0% 6.42 (3.45 to 11.95), 0% 
Liver transplantation 
  N=2 studies 10.89 (2.01 to 58.99), 0% 3.40 (0.96 to 12.00), 0% 
All liver events 
  N=6 studies 5.58 (3.70 to 8.40), 0% 6.31, (4.60 to 8.65), 0% 
All results are fixed effect meta-analysis   
e-Appendix 5. Meta-analysis of events by NAFLD with NASH vs NALFD without NASH 
All -cause mortality 
Stage 0 vs 1 
 
 
  
Stage 0 vs 2 
 
 
  
.
.
NASH
Hagstrom 2017 [NASH]
Ito 2019 [NASH]
Younossi 2017 [NASH]
Leung 2017 [NASH]
Peleg 2018 [NASH]
Subtotal  (I-squared = 0.0%, p = 0.562)
No NASH
Hagstrom 2017 [NoNASH]
Leung 2017 [NoNASH]
Peleg 2018 [NoNASH]
Younossi 2017 [NoNASH]
Ito 2019 [NoNASH]
Subtotal  (I-squared = 0.0%, p = 0.934)
ID
Study
1.12 (0.66, 1.90)
0.69 (0.03, 15.64)
4.58 (0.30, 69.99)
(Excluded)
(Excluded)
1.24 (0.74, 2.07)
1.40 (0.84, 2.32)
0.69 (0.03, 13.60)
2.63 (0.16, 43.07)
1.19 (0.10, 13.93)
(Excluded)
1.40 (0.85, 2.28)
Risk (95% CI)
Relative
37/117
1/38
8/25
0/17
1/5
47/202
13/32
0/15
4/23
0/1
0/0
17/71
Treatment
Events,
13/46
0/8
0/6
0/23
0/0
13/83
34/117
2/54
0/6
10/49
0/53
46/279
Control
Events,
1.25 .5 2 4 8
All-cause Mortality NAFLD stage 0 vs stage 2
Stage 0 vs 3  
 
 
  
.
.
NASH
Hagstrom 2017 [NASH]
Ito 2019 [NASH]
Younossi 2017 [NASH]
Leung 2017 [NASH]
Peleg 2018 [NASH]
Subtotal  (I-squared = 0.0%, p = 0.630)
No NASH
Hagstrom 2017 [NoNASH]
Leung 2017 [NoNASH]
Peleg 2018 [NoNASH]
Younossi 2017 [NoNASH]
Ito 2019 [NoNASH]
Subtotal  (I-squared = 0.0%, p = 0.592)
ID
Study
1.81 (1.06, 3.09)
1.05 (0.05, 20.00)
5.83 (0.39, 86.35)
(Excluded)
(Excluded)
1.99 (1.17, 3.41)
2.68 (1.71, 4.20)
0.79 (0.04, 15.46)
2.33 (0.13, 42.44)
3.97 (1.90, 8.30)
(Excluded)
2.60 (1.65, 4.09)
Risk (95% CI)
Relative
25/49
2/42
17/41
0/22
1/1
45/155
7/9
0/13
2/14
2/2
0/0
11/38
Treatment
Events,
13/46
0/8
0/6
0/23
0/0
13/83
34/117
2/54
0/6
10/49
0/53
46/279
Control
Events,
1.25 .5 2 4 8
All-cause Mortality NAFLD stage 0 vs stage 3
Stage 0 vs 4 
 
  
Liver mortality 
Stage 0 vs 1 
 
  
Stage 0 vs 2  
 
 
  
.
.
NASH
Hagstrom 2017 [NASH]
Ito 2018 [NASH]
Younossi 2017 [NASH]
Leung 2017 [NASH]
Peleg 2018 [NASH]
Subtotal  (I-squared = 0.0%, p = 0.998)
No NASH
Hagstrom 2017 [NoNASH]
Ito 2018 [NoNASH]
Leung 2017 [NoNASH]
Peleg 2018 [NoNASH]
Younossi 2017 [NoNASH]
Subtotal  (I-squared = .%, p = .)
ID
Study
0.79 (0.15, 4.15)
0.71 (0.03, 16.04)
0.81 (0.04, 17.75)
(Excluded)
(Excluded)
0.78 (0.21, 2.92)
7.31 (0.68, 78.10)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
7.31 (0.68, 78.10)
Risk (95% CI)
Relative
4/117
1/37
1/25
0/17
0/5
6/201
2/32
0/1
0/15
0/23
0/1
2/72
Treatment
Events,
2/46
0/8
0/6
0/23
0/0
2/83
1/117
0/53
0/54
0/6
0/49
1/279
Control
Events,
1.25 .5 2 4 8
Liver Mortality NAFLD stage 0 vs stage 2
Stage 0 vs 3 
 
  
.
.
NASH
Hagstrom 2017 [NASH]
Ito 2018 [NASH]
Younossi 2017 [NASH]
Leung 2017 [NASH]
Peleg 2018 [NASH]
Subtotal  (I-squared = 0.0%, p = 0.882)
No NASH
Hagstrom 2017 [NoNASH]
Ito 2018 [NoNASH]
Leung 2017 [NoNASH]
Peleg 2018 [NoNASH]
Younossi 2017 [NoNASH]
Subtotal  (I-squared = .%, p = .)
ID
Study
0.94 (0.14, 6.39)
1.05 (0.05, 20.00)
2.17 (0.14, 34.33)
(Excluded)
(Excluded)
1.24 (0.31, 4.93)
26.00 (2.60, 260.04)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
26.00 (2.60, 260.04)
Risk (95% CI)
Relative
2/49
2/42
6/41
0/22
0/1
10/155
2/9
0/0
0/13
0/14
0/2
2/38
Treatment
Events,
2/46
0/8
0/6
0/23
0/0
2/83
1/117
0/53
0/54
0/6
0/49
1/279
Control
Events,
1.25 .5 2 4 8
Liver Mortality NAFLD stage 0 vs stage 3
Stage 0 vs 4 
 
 
 
  
.
.
NASH
Hagstrom 2017 [NASH]
Ito 2018 [NASH]
Younossi 2017 [NASH]
Leung 2017 [NASH]
Peleg 2018 [NASH]
Subtotal  (I-squared = 0.0%, p = 0.669)
No NASH
Hagstrom 2017 [NoNASH]
Leung 2017 [NoNASH]
Peleg 2018 [NoNASH]
Ito 2018 [NoNASH]
Younossi 2017 [NoNASH]
Subtotal  (I-squared = 0.0%, p = 0.914)
ID
Study
1.44 (0.14, 14.81)
5.00 (0.28, 90.18)
6.05 (0.40, 91.19)
(Excluded)
(Excluded)
3.74 (0.83, 16.83)
7.87 (0.36, 169.96)
15.00 (0.65, 344.64)
6.30 (0.40, 99.29)
(Excluded)
(Excluded)
8.17 (1.27, 52.58)
Risk (95% CI)
Relative
1/16
2/8
9/21
0/37
1/8
13/90
0/4
1/10
4/9
0/0
0/1
5/24
Treatment
Events,
2/46
0/8
0/6
0/23
0/0
2/83
1/117
0/54
0/6
0/53
0/49
1/279
Control
Events,
1.25 .5 2 4 8
Liver Mortality NAFLD stage 0 vs stage 4
Liver transplant 
Stage 0 vs 1 
 
 
 
  
Stage 0 vs 2 
 
 
  
.
.
NASH
Hagstrom 2017 [NASH]
Ito 2019 [NASH]
Leung 2017 [NASH]
Peleg 2018 [NASH]
Subtotal  (I-squared = .%, p = .)
No NASH
Hagstrom 2017 [NoNASH]
Peleg 2018[NoNASH]
Ito 2019 [NoNASH]
Leung 2017 [NoNASH]
Subtotal  (I-squared = 0.0%, p = 0.364)
ID
Study
(Excluded)
(Excluded)
(Excluded)
(Excluded)
. (., .)
10.73 (0.45, 257.25)
1.46 (0.08, 26.97)
(Excluded)
(Excluded)
3.50 (0.52, 23.69)
Risk (95% CI)
Relative
0/37
0/17
0/5
0/176
1/32
2/23
0/1
0/15
3/71
Treatment
Events,
.
0/8
0/8
0/0
0/62
0/117
0/6
0/53
0/69
0/245
Control
Events,
1.25 .5 2 4 8
Liver transplantation NAFLD stage 0 vs stage 2
Stage 0 vs 3 
. metan  n_3 n_3_no n_0 n_0_no, label(namevar= var1 ) nowt  xlabel(0.25,0.5,1,2,4,8) counts  texts(140) effect (Relative Risk) title (Liver transplant NAFLD 
stage 0 vs stage 2) by(NASH) 
Insufficient data to perform this meta-analysis 
  
Stage 0 vs 4 
 
 
 
 
  
All liver events 
Stage 0 vs 1  
 
  
Stage 0 vs 2 
 
  
Stage 0 vs 3 
 
 
  
Stage 0 vs 4 
 
 
 
 
  
.
.
NASH
Hagstrom 2017 [NASH]
Ito 2019 [NASH]
Leung 2017 [NASH]
Peleg 2018 [NASH]
Subtotal  (I-squared = 0.0%, p = 0.708)
No NASH
Hagstrom 2017 [NoNASH]
Leung 2017 [NoNASH]
Peleg 2018 [NoNASH]
Ito 2019 [NoNASH]
Subtotal  (I-squared = 0.0%, p = 0.845)
ID
Study
7.47 (3.16, 17.67)
7.00 (0.42, 116.91)
1.89 (0.08, 44.64)
(Excluded)
6.48 (2.89, 14.55)
7.43 (2.67, 20.69)
10.80 (1.08, 108.12)
13.30 (0.92, 192.97)
(Excluded)
9.80 (3.12, 30.76)
Risk (95% CI)
Relative
13/16
3/8
1/37
6/8
23/69
4/9
2/10
9/9
0/0
15/28
Treatment
Events,
5/46
0/8
0/23
0/0
5/77
7/117
1/54
0/6
0/53
8/230
Control
Events,
1.25 .5 2 4 8
Liver all events NAFLD stage 0 vs stage 4
a-Appendix 6. HRQoL by fibrosis stage across individual studies  
 Stage 0 
 
Stage 1 
 
Stage 2 
 
Stage 3 Stage 4 
 
David (2009) N, median (IQR) N, median (IQR) N, median (IQR) N, median (IQR) N, median (IQR) 
SF-36 PCS 167, 50 (42.5, 56) 211, 50 (39, 54) 138, 47 (36, 54) 131, 48 (37, 53) 66, 37 (31, 48) 
SF-36 MCS NR NR NR NR NR 
Huber (2018) N, mean (SD) N, mean (SD) N, mean (SD) N, mean (SD) N, mean (SD) 
CLDQ total 36, 4.76 NR 74, 5.23 NR 67, 5.10 NR 82, 4.90 NR N, mean (SD) 
Younossi (2018) N, mean (SD) N, mean (SD) N, mean (SD) N, mean (SD) N, mean (SD) 
SF-36 PCS - - 25, 45.0 (8.7) 47, 43.4 (10.3) - 
SF-36 MCS - - 25, 51.0 (9.6) 47, 50.6 (12.7)  - 
CLDQ total - - 25, 4.83 (1.10) 47, 4.91 (1.25) - 
CLDQ: Chronic Liver Disease Questionnaire; MCS: Mental Component Score NR: not reported; PCS: Physical Component Score; 
SD: standard deviation; SF-36: Short Form-36 
  
e-Appendix 7.  Univariate meta-regression analysis  
 Fibrosis stage 0 
vs. 1 
Fibrosis stage 0  
vs. 2 
Fibrosis stage 0  
vs. 3 
Fibrosis stage 0  
vs. 4 
All-cause mortality 
Retrospective vs. prospective 
study design 
P = 0.774 
 
P = 0.47 P = 0.48 P = 0.20 
High vs. moderate risk of bias P = 0.92 P = 0.67 P = 0.67 P = 0.46 
Duration of follow up (years) P = 0.36 P = 0.11 P = 0.46 P = 0.12 
All-liver related events  
Retrospective vs. prospective 
study design 
P = 0.41 P = 0.97 P = 0.28 P = 0.47 
High vs. moderate risk of bias P = 0.670 P = 0.80 P = 0.73 P = 0.98 
Duration of follow up (years) P = 0.61 P = 0.13 P = 0.28 P = 0.51 
eAppendix 8. - Assessment of small study bias  
 
 
Egger test p-value=0.996 
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e-Appendix 9. – GRADE assessment of quality of evidence for liver fibrosis as prognostic marker for NAFLD 
 
Study design Risk of 
bias 
Indirectness Imprecision Additional considerations5 Quality  
All-cause mortality 
 
Observational Serious1 Not serious2 Not serious3 large effect; no publication bias; confounder adjusted  
 
High 
 
Liver-related mortality 
 
Observational 
 
Serious1 
 
Not serious2 
 
Serious4 
 
large effect; no publication bias; confounder adjusted  
 
Moderate 
 
Liver transplantation  
 
Observational 
 
Serious1 
 
Not serious2 
 
Serious4 
 
Large effect; no publication bias; confounder adjusted  
 
Low 
 
All-liver events 
 
Observational 
 
Serious1 
 
Serious6 
 
Not serious3 
 
Large effect; no publication bias; confounder adjusted  
 
Low 
 
HRQoL 
 
Observational 
 
Serious1 
 
Not serious2 
 
Serious7 
 
Large effect; no publication bias; confounder adjusted  
 
Low 
 
1. risk of bias for individual studies judged to be moderate or high (see Table 2); 2. appropriate population and outcomes; 3. sufficient number of events; 4. 
insufficient number of events (especially for stage 0 fibrosis); 5. positive considerations can allow upgrading of GRADE rating; 6. Inconsistent definition of 
composite outcome of all liver events across studies; 7. Small number of studies; 8: From Iorio et al (2014): High: very confident that the true prognosis 
(probability of future events) lies close to that of the estimate; Moderate: moderately confident that the true prognosis (probability of future events) is likely to 
be close to the estimate, but there is a possibility that it is substantially different; Low: confidence in the estimate is limited: the true prognosis (probability of  
BACKGROUND AND CONTEXT: The stage (or extent) of liver fibrosis, confirmed by biopsy, 
is believed to be prognostic factor for risk death in people with non-alcoholic fatty liver disease 
(NAFLD).  
NEW FINDINGS: This systematic review and meta-analysis of 4428 patients in 13 studies found 
that, with and without adjustments for potential confounding factors, fibrosis stage was 
associated with all-cause mortality, liver-related mortality, and morbidity in patients with 
NAFLD. 
LIMITATIONS: This was a systematic review of previous publications. There was insufficient 
evidence to determine whether fibrosis stage associated with health-related quality of life or 
whether a change in fibrosis stage is associated with response to treatment.  
IMPACT: It is important to monitor liver fibrosis stage in patients with NAFLD. Studies are 
needed to determine whether change in fibrosis stage can be used as an endpoint for treatment of 
NAFLD. 
 
Lay Summary: In an analysis of data from 13 previously published studies, this study found 
stage of fibrosis, determined by biopsy analysis, to be associated with mortality and morbidities 
in patients with NAFLD.  
 
